Evidence map›Paper›PMID 40335555›Full record

ArticleScientific reports2025

Comparative analysis of oncologic outcomes in surgically treated patients with renal cell carcinoma and renal vein thrombosis by pathologic subtypes.

Dongrul Shin, Bumjin Lim, Cheryn Song, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Bumsik Hong, Chang Wook Jeong, Jang Hee Han and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dongrul ShinDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
Bumjin LimDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
Cheryn SongDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
Dalsan YouDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
In Gab JeongDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
Jun Hyuk HongDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
Hanjong AhnDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
Bumsik HongDepartment of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
Chang Wook JeongDepartment of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Jang Hee Han *Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. urohan@snu.ac.kr.
Jungyo Suh *Department of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea. crazyslime@gmail.com.

Funding

National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) RS-2024-00392315
6 · The paper itself

Abstract

This study compares recurrence-free survival (RFS) and overall survival (OS) in patients with non-clear cell (nccRCC) and clear cell renal cell carcinoma (ccRCC) undergoing surgical nephrectomy with thrombectomy (SNTx) for RCC with venous thrombus. Data from patients who underwent SNTx at two tertiary centers (June 1990-December 2022) were retrospectively reviewed. Patients were grouped as ccRCC or nccRCC and stratified by metastasis status at surgery. Primary endpoints were RFS and OS for metastasis-naive RCC and OS for the entire cohort, including both metastasis-naive and metastatic RCC. Kaplan-Meier analysis with log-rank tests and adjusted multivariable Cox proportional hazards models were performed, with TN adjustments for the metastasis-naive group and TNM adjustments for the entire population. Among 604 patients, 504 (83.5%) were ccRCC. In nccRCC, 44 (44.0%) were papillary, 17 (17.0%) were chromophobe, and 39 (39.0%) were rare subtypes, most commonly TFE3 rearranged RCC, followed by the RCC not otherwise specified subtype (according to the 2022 World Health Organization Classification of RCC). Median OS was 85.8 months for ccRCC, 37.7 for papillary, 90.2 for chromophobe, and 16.9 for rare subtypes. Rare RCC histology was significantly associated with worse RFS (HR 1.63, p = 0.038) and OS (HR 1.82, p = 0.039) in metastasis-naive RCC. For the entire cohort including metastatic diseases, rare subtypes had worse OS (HR 2.20, p < 0.001), while other nccRCC subtypes did not differ significantly from ccRCC in OS. In patients with RCC with venous thrombosis, rare nccRCC subtypes exhibited poorer survival outcomes, even after adjustment for TN(M) stage.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRenal VeinsVenous ThrombosisAdultAgedFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNephrectomyRetrospective StudiesThrombectomyTreatment OutcomeChromophobe RCCClear cell RCCNon-clear cell RCCPapillary RCCRenal cell carcinomaVenous thrombosis

Identifiers

PMID40335555
PMCPMC12059190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.